Zinc finger protein 703 (ZNF703)

Zinc finger protein 703 (ZNF703) is a highly conserved member of the NET/NLZ family of zinc finger transcriptional repressors, functioning mainly as a nuclear co-repressor or co-activator involved in the regulation of gene expression during embryonic development and cell fate determination[1][2][3][4]. ZNF703 is essential for proper patterning of neural crest, placodes, mesoderm, and is critical in early neural development[1][2]. In cancer, aberrant expression or amplification of ZNF703 (notably at chromosome 8p12) leads to enhanced tumor cell proliferation, metastasis, therapy resistance, and cancer stem cell properties—especially in luminal B breast cancer where it is a driver of poor prognosis[2][3][4]. Mechanistically, ZNF703 operates in nuclear complexes with co-repressors such as DCAF7, PHB2, and NCOR2, modulating key transcriptional programs, including those regulated by estrogen receptor and E2F1, and participates in oncogenic processes like epithelial–mesenchymal transition and Akt/mTOR pathway activation. Currently, no direct drugs target ZNF703, but it is recognized as an emerging therapeutic target due to its oncogenic role and potential as a diagnostic/prognostic biomarker[2][3][4].

Other names

ZNF703ZEPPO1ZPO1FLJ14299ZNF503LNLZ1zinc finger elbow-related proline domain protein 1

Not directly targeted by drugs, but when targeted, the likely mechanisms would include inhibition of its transcriptional co-repressor/oncogenic activity, disruption of its interaction with nuclear co-repressor complexes, or prevention of its involvement in transcriptional regulation pathways (ER, E2F1, CLDN4/EMT, Akt/mTOR)